Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans

Fungal Genetics and Biology

Volumn 46, Issue 9, 2009, Pages 714-720

  Chen, Chia Geun ^a   Yang, Yun Liang ^b   Tseng, Kuo Yun ^c   Shih, Hsin I ^b   Liou, Ci Hong ^c   Lin, Chih Chao ^c   Lo, Hsiu Jung ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Candida albicans; Drug resistance; Efflux pump

Indexed keywords

FLUCONAZOLE; FUNGAL PROTEIN; MICONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; REP1 PROTEIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SACCHAROMYCES CEREVISIAE;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA ALBICANS; CANDIDIASIS; CLONING, MOLECULAR; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE DELETION; GENE EXPRESSION REGULATION, FUNGAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; RNA, FUNGAL; RNA, MESSENGER;

CANDIDA ALBICANS; SACCHAROMYCES CEREVISIAE;

EID: 67650572854     PISSN: 10871845     EISSN: 10960937     Source Type: Journal    
DOI: 10.1016/j.fgb.2009.06.003     Document Type: Article

References (51)

1. Alarco A.M., and Raymond M. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J. Bacteriol. 181 (1999) 700-708
2. Chen C.G., Yang Y.L., Shih H.I., Su C.L., and Lo H.J. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob. Agents Chemother. 48 (2004) 4505-4512
3. Chu S., DeRisi J., Eisen M., Mulholland J., Botstein D., Brown P.O., and Herskowitz I. The transcriptional program of sporulation in budding yeast. Science 282 (1998) 699-705
4. Chu S., and Herskowitz I. Gametogenesis in yeast is regulated by a transcriptional cascade dependent on Ndt80. Mol. Cell 1 (1998) 685-696
5. Clinical Laboratory Standards Institute, CLSI, 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27A, Wayne, PA.
6. Coste A.T., Karababa M., Ischer F., Bille J., and Sanglard D. TAC 1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3 (2004) 1639-1652
7. Coste A.T., Ramsdale M., Ischer F., and Sanglard D. Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae. Microbiology 154 (2008) 1491-1501
8. Dunkel N., Blass J., Rogers P.D., and Morschhäuser J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69 (2008) 827-840
9. Dunkel N., Liu T.T., Barker K.S., Homayouni R., Morschhäuser J., and Rogers P.D. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7 (2008) 1180-1190
10. Fling M.E., Kopf J., Tamarkin A., Gorman J.A., Smith H.A., and Koltin Y. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet. 227 (1991) 318-329
11. Franz R., Kelly S.L., Lamb D.C., Kelly D.E., Ruhnke M., and Morschhäuser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42 (1998) 3065-3072
12. Gillum A.M., Tsay E.Y., and Kirsch D.R. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198 (1984) 179-182
13. Gupta V., Kohli A., Krishnamurthy S., Puri N., Aalamgeer S.A., Panwar S., and Prasad R. Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr. Genet. 34 (1998) 192-199
14. Holmes A.R., Lin Y.H., Niimi K., Lamping E., Keniya M., Niimi M., Tanabe K., Monk B.C., and Cannon R.D. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob. Agents Chemother. 52 (2008) 3851-3862
15. Hung C.C., Yang Y.L., Lauderdale T.L., McDonald L.C., Hsiao C.F., Cheng H.H., Ho Y.A., and Lo H.J. Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J. Clin. Microbiol. 43 (2005) 1600-1603
16. Joseph-Horne T., and Hollomon D.W. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol. Lett. 149 (1997) 141-149
17. Kelly S.L., Lamb D.C., and Kelly D.E. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol. Lett. 180 (1999) 171-175
18. Lamb D.C., Kelly D.E., Schunck W.H., Shyadehi A.Z., Akhtar M., Lowe D.J., Baldwin B.C., and Kelly S.L. The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272 (1997) 5682-5688
19. Lamb D.C., Kelly D.E., White T.C., and Kelly S.L. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob. Agents Chemother. 44 (2000) 63-67
20. Lee M.K., Williams L.E., Warnock D.W., and Arthington-Skaggs B.A. Drug resistance genes and trailing growth in Candida albicans isolates. J. Antimicrob. Chemother. 53 (2004) 217-224
21. Lo H.J., Kohler J.R., DiDomenico B., Loebenberg D., Cacciapuoti A., and Fink G.R. Nonfilamentous C. albicans mutants are avirulent. Cell 90 (1997) 939-949
22. Lo H.J., Wang J.S., Lin C.Y., Chen C.G., Hsiao T.Y., Hsu C.T., Su C.L., Fann M.J., Ching Y.T., and Yang Y.L. Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans. Antimicrob. Agents Chemother. 49 (2005) 1213-1215
23. Lupetti A., Danesi R., Campa M., Del T.M., and Kelly S. Molecular basis of resistance to azole antifungals. Trend. Mol. Med. 8 (2002) 76-81
24. Marichal P., Koymans L., Willemsens S., Bellens D., Verhasselt P., Luyten W., Borgers M., Ramaekers F.C., Odds F.C., and Bossche H.V. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145 (1999) 2701-2713
25. Montano S.P., Cote M.L., Fingerman I., Pierce M., Vershon A.K., and Georgiadis M.M. Crystal structure of the DNA-binding domain from Ndt80, a transcriptional activator required for meiosis in yeast. Proc. Natl. Acad. Sci. USA 99 (2002) 14041-14046
26. Morschhäuser J., Barker K.S., Liu T.T., Blass-Warmuth J., Homayouni R., and Rogers P.D. The Transcription Factor Mrr1p Controls Expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathogenesis 3 (2007) 1603-1616
27. Muller F.M., Weig M., Peter J., and Walsh T.J. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. 46 (2000) 338-340
28. Oliver B.G., Song J.L., Choiniere J.H., and White T.C. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryot. Cell 6 (2007) 2231-2239
29. Perea S., Lopez-Ribot J.L., Kirkpatrick W.R., McAtee R.K., Santillan R.A., Martinez M., Calabrese D., Sanglard D., and Patterson T.F. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45 (2001) 2676-2684
30. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., and Messer S.A. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbiol. 39 (2001) 3254-3259
31. Pfaller M.A., Diekema D.J., Messer S.A., Boyken L., and Hollis R.J. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001. J. Clin. Microbiol. 41 (2003) 1440-1446
32. Puri N., Krishnamurthy S., Habib S., Hasnain S.E., Goswami S.K., and Prasad R. CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole. FEMS Microbiol. Lett. 180 (1999) 213-219
33. Rognon B., Kozovska Z., Coste A.T., Pardini G., and Sanglard D. Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152 (2006) 3701-3722
34. Sanglard D., Ischer F., Koymans L., and Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42 (1998) 241-253
35. Sanglard D., Ischer F., Monod M., and Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40 (1996) 2300-2305
36. Sanglard D., Ischer F., Monod M., and Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143 (1997) 405-416
37. Sanglard D., Ischer F., Parkinson T., Falconer D., and Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47 (2003) 2404-2412
38. Sherman F. Getting started with yeast. Method. Enzymol. 350 (2002) 3-41
39. Tapia C., Leon E., and Palavecino E. Antifungal susceptibility of yeasts by Etest. Comparison of 3 media. Rev. Med. Chil. 131 (2003) 299-302
40. Tsao S., Rahkhoodaee F., and Raymond M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53 (2009) 1344-1352
41. Wang J.S., Yang Y.L., Wu C.G., Ouyang K.J., Tseng K.Y., Chen C.G., Wang H., and Lo H.J. The DNA binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans. J. Med. Microbiol. 55 (2006) 1403-1411
42. White T.C. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41 (1997) 1482-1487
43. White T.C., Marr K.A., and Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11 (1998) 382-402
44. Wilson R.B., Davis D., and Mitchell A.P. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J. Bacteriol. 181 (1999) 1868-1874
45. Xu Y., Chen L., and Li C. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J. Antimicrob. Chemother. 61 (2008) 798-804
46. Yan L., Zhang J., Li M., Cao Y., Xu Z., Gao P., Wang Y., and Jiang Y. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim. Biophys. Sin. (Shanghai). 40 (2008) 1048-1060
47. Yang Y.L., Cheng H.H., Ho Y.A., Hsiao C.F., and Lo H.J. Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J. Microbiol. Immunol. Infect. 36 (2003) 187-191
48. Yang Y.L., Cheng H.H., and Lo H.J. In vitro activity of voriconazole against Candida species isolated in Taiwan. Int. J. Antimicrob. Agents 24 (2004) 294-296
49. Yang Y.L., Li S.Y., Cheng H.H., and Lo H.J. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn. Microbiol. Infect. Dis. 51 (2005) 179-183
50. Yang Y.L., and Lo H.J. Mechanisms of antifungal agent resistance. J. Microbiol. Immunol. Infect. 34 (2001) 79-86
51. Znaidi S., Weber S., Al-Abdin O.Z., Bomme P., Saidane S., Drouin S., Lemieux S., De Deken X., Robert F., and Raymond M. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell 7 (2008) 836-847